Skip to main content
. 2017 Oct 23;2:25. Originally published 2017 Apr 7. [Version 2] doi: 10.12688/wellcomeopenres.11253.2

Figure 12. Validation of novel steroidogenic genes.

Figure 12.

( a) Immunohistochemistry for GRAMD1B in human fetal testis at 9 wpc. NR5A1 (SF-1) was used to highlight Leydig cells (green). DAPI was used to counterstain nuclei (blue) and to highlight the outer capsule. Scale bars, 50 µm (top panels) and 20 µm (bottom panels). ( b) Immunohistochemistry of RMDN2 performed as above. Scale bars, 50 µm (top panels) and 20 µm (bottom panels). ( c) Immunohistochemistry of GRAMD1B and RMDN2 in the fetal adrenal gland at 9 wpc. NR5A1 (SF-1) was used to highlight the definitive zone and fetal zone cells (green). DAPI was used to counterstain nuclei (blue) and to highlight the outer capsule. Scale bars, 100 µm. ( d) Immunohistochemistry for FOXO4 in human fetal testis at 11 wpc. NR5A1 (SF-1) was used to highlight Leydig cells (green). DAP-I was used to counterstain nuclei (blue). Scale bar, 100 µm (top panels) and 20 µm (bottom panels).